RATIONALE: Limited data exist about the international burden of severe sepsis in critically ill children. OBJECTIVES: To characterize the global prevalence, therapies, and outcomes of severe sepsis in pediatric intensive care units to better inform interventional trials. METHODS: A point prevalence study was conducted on 5 days throughout 2013-2014 at 128 sites in 26 countries. Patients younger than 18 years of age with severe sepsis as defined by consensus criteria were included. Outcomes were severe sepsis point prevalence, therapies used, new or progressive multiorgan dysfunction, ventilator- and vasoactive-free days at Day 28, functional status, and mortality. MEASUREMENTS AND MAIN RESULTS: Of 6,925 patients screened, 569 had severe sepsis (prevalence, 8.2%; 95% confidence interval, 7.6-8.9%). The patients' median age was 3.0 (interquartile range [IQR], 0.7-11.0) years. The most frequent sites of infection were respiratory (40%) and bloodstream (19%). Common therapies included mechanical ventilation (74% of patients), vasoactive infusions (55%), and corticosteroids (45%). Hospital mortality was 25% and did not differ by age or between developed and resource-limited countries. Median ventilator-free days were 16 (IQR, 0-25), and vasoactive-free days were 23 (IQR, 12-28). Sixty-seven percent of patients had multiorgan dysfunction at sepsis recognition, with 30% subsequently developing new or progressive multiorgan dysfunction. Among survivors, 17% developed at least moderate disability. Sample sizes needed to detect a 5-10% absolute risk reduction in outcomes within interventional trials are estimated between 165 and 1,471 [corrected] patients per group. CONCLUSIONS: Pediatric severe sepsis remains a burdensome public health problem, with prevalence, morbidity, and mortality rates similar to those reported in critically ill adult populations. International clinical trials targeting children with severe sepsis are warranted.
RATIONALE: Limited data exist about the international burden of severe sepsis in critically ill children. OBJECTIVES: To characterize the global prevalence, therapies, and outcomes of severe sepsis in pediatric intensive care units to better inform interventional trials. METHODS: A point prevalence study was conducted on 5 days throughout 2013-2014 at 128 sites in 26 countries. Patients younger than 18 years of age with severe sepsis as defined by consensus criteria were included. Outcomes were severe sepsis point prevalence, therapies used, new or progressive multiorgan dysfunction, ventilator- and vasoactive-free days at Day 28, functional status, and mortality. MEASUREMENTS AND MAIN RESULTS: Of 6,925 patients screened, 569 had severe sepsis (prevalence, 8.2%; 95% confidence interval, 7.6-8.9%). The patients' median age was 3.0 (interquartile range [IQR], 0.7-11.0) years. The most frequent sites of infection were respiratory (40%) and bloodstream (19%). Common therapies included mechanical ventilation (74% of patients), vasoactive infusions (55%), and corticosteroids (45%). Hospital mortality was 25% and did not differ by age or between developed and resource-limited countries. Median ventilator-free days were 16 (IQR, 0-25), and vasoactive-free days were 23 (IQR, 12-28). Sixty-seven percent of patients had multiorgan dysfunction at sepsis recognition, with 30% subsequently developing new or progressive multiorgan dysfunction. Among survivors, 17% developed at least moderate disability. Sample sizes needed to detect a 5-10% absolute risk reduction in outcomes within interventional trials are estimated between 165 and 1,471 [corrected] patients per group. CONCLUSIONS: Pediatric severe sepsis remains a burdensome public health problem, with prevalence, morbidity, and mortality rates similar to those reported in critically ill adult populations. International clinical trials targeting children with severe sepsis are warranted.
Entities:
Keywords:
multiple organ failure; pediatrics; sepsis
Authors: Scott L Weiss; Julie C Fitzgerald; Edward Vincent Faustino; Marino S Festa; Ericka L Fink; Philippe Jouvet; Jenny L Bush; Niranjan Kissoon; John Marshall; Vinay M Nadkarni; Neal J Thomas Journal: Pediatr Crit Care Med Date: 2014-09 Impact factor: 3.624
Authors: Scott L Weiss; Julie C Fitzgerald; Fran Balamuth; Elizabeth R Alpern; Jane Lavelle; Marianne Chilutti; Robert Grundmeier; Vinay M Nadkarni; Neal J Thomas Journal: Crit Care Med Date: 2014-11 Impact factor: 7.598
Authors: Simon Nadel; Brahm Goldstein; Mark D Williams; Heidi Dalton; Mark Peters; William L Macias; Shamel A Abd-Allah; Howard Levy; Robinette Angle; Dazhe Wang; David P Sundin; Brett Giroir Journal: Lancet Date: 2007-03-10 Impact factor: 79.321
Authors: Cláudio F de Oliveira; Débora S F de Oliveira; Adriana F C Gottschald; Juliana D G Moura; Graziela A Costa; Andréa C Ventura; José Carlos Fernandes; Flávio A C Vaz; Joseph A Carcillo; Emanuel P Rivers; Eduardo J Troster Journal: Intensive Care Med Date: 2008-03-28 Impact factor: 17.440
Authors: Andrea Wolfler; Paolo Silvani; Massimo Musicco; Massimo Antonelli; Ida Salvo Journal: Intensive Care Med Date: 2008-05-24 Impact factor: 17.440
Authors: Fran Balamuth; Scott L Weiss; Mark I Neuman; Halden Scott; Patrick W Brady; Raina Paul; Reid W D Farris; Richard McClead; Katie Hayes; David Gaieski; Matt Hall; Samir S Shah; Elizabeth R Alpern Journal: Pediatr Crit Care Med Date: 2014-11 Impact factor: 3.624
Authors: Amanda Ruth; Courtney E McCracken; James D Fortenberry; Matthew Hall; Harold K Simon; Kiran B Hebbar Journal: Pediatr Crit Care Med Date: 2014-11 Impact factor: 3.624
Authors: Hector R Wong; Shelia Salisbury; Qiang Xiao; Natalie Z Cvijanovich; Mark Hall; Geoffrey L Allen; Neal J Thomas; Robert J Freishtat; Nick Anas; Keith Meyer; Paul A Checchia; Richard Lin; Thomas P Shanley; Michael T Bigham; Anita Sen; Jeffrey Nowak; Michael Quasney; Jared W Henricksen; Arun Chopra; Sharon Banschbach; Eileen Beckman; Kelli Harmon; Patrick Lahni; Christopher J Lindsell Journal: Crit Care Date: 2012-10-01 Impact factor: 9.097
Authors: Robert B Lindell; Akira Nishisaki; Scott L Weiss; Fran Balamuth; Danielle M Traynor; Marianne R Chilutti; Robert W Grundmeier; Julie C Fitzgerald Journal: Crit Care Med Date: 2019-02 Impact factor: 7.598
Authors: Kristin H Gigli; Billie S Davis; Jonathan G Yabes; Chung-Chou H Chang; Derek C Angus; Tina Batra Hershey; Jennifer R Marin; Grant R Martsolf; Jeremy M Kahn Journal: Pediatrics Date: 2020-07 Impact factor: 7.124
Authors: Scott L Weiss; Julie C Fitzgerald; Edward Vincent Faustino; Marino S Festa; Ericka L Fink; Philippe Jouvet; Jenny L Bush; Niranjan Kissoon; John Marshall; Vinay M Nadkarni; Neal J Thomas Journal: Pediatr Crit Care Med Date: 2014-09 Impact factor: 3.624
Authors: Julie E Stark; Amy M Opoka; Jaya Mallela; Prasad Devarajan; Qing Ma; Nick C Levinsky; Keith F Stringer; Hector R Wong; Matthew N Alder Journal: Am J Physiol Renal Physiol Date: 2020-02-18
Authors: Adriana D Hernandez-García; Daniel A Columbus; Rodrigo Manjarín; Hanh V Nguyen; Agus Suryawan; Renán A Orellana; Teresa A Davis Journal: Am J Physiol Endocrinol Metab Date: 2016-09-13 Impact factor: 4.310
Authors: Richard W Pierce; Veronika Shabanova; Michael Canarie; Mathew Pinto; Yong Sing da Silva; Vineet Bhandari; John S Giuliano Journal: Shock Date: 2019-03 Impact factor: 3.454